Unknown

Dataset Information

0

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.


ABSTRACT:

SUBMITTER: Pattanaik S 

PROVIDER: S-EPMC6517182 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.

Pattanaik Smita S   Mavuduru Ravimohan S RS   Panda Arabind A   Mathew Joseph L JL   Agarwal Mayank M MM   Hwang Eu Chang EC   Lyon Jennifer A JA   Singh Shrawan K SK   Mandal Arup K AK  

The Cochrane database of systematic reviews 20181116


<h4>Background</h4>Benign prostatic hyperplasia (BPH) refers to non-malignant enlargement of the prostate gland that may cause bothersome lower urinary tract symptoms (LUTS). Alpha-blockers (ABs) and 5-alpha reductase inhibitors (5-ARIs) are the mainstay of medical treatment. Recently, phosphodiesterase inhibitors (PDEIs) that so far have been used mainly to treat erectile dysfunction were introduced to treat male LUTS.<h4>Objectives</h4>To assess the effects of PDEIs compared to placebo and oth  ...[more]

Similar Datasets

| S-EPMC5563527 | biostudies-literature
| S-EPMC6125595 | biostudies-literature
| S-EPMC6486059 | biostudies-literature
| S-EPMC3962766 | biostudies-literature
| S-EPMC5753557 | biostudies-literature
| S-EPMC8317814 | biostudies-literature
| S-EPMC9778582 | biostudies-literature
| S-EPMC6504530 | biostudies-literature